Overview

A Repeat Dose Positron Emission Tomography Study With GSK1144814

Status:
Completed
Trial end date:
2009-10-25
Target enrollment:
Participant gender:
Summary
This study described in the present protocol consists of two parts. Part A is a multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ascending doses of GSK1144814. Part B is an open label design in healthy male subjects to assess the GSK1144814 Neurokinin1 receptor occupancy.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Midazolam